3National Cimmittee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing[S].Tenth irformaticnal Supplement.M100-S10,2000.1-54.
4Choury D,Szajnert M F,Joly-Guillou M L,et al.Nucleotide sequence of the blaRTG-2(CARB-5) gene and phylogeny of a new group of carbenicillinases[J].Antimicrob Agents Chemogher,2000,44:1070-1074.
5Weldhagen GF,Prinsloo A.Molecular detection of GES-2 extended spectrum beta-lactamase producing Pseudomonas aeruginosa in Pretoria,South Africa.Int J Antimicrob Agents,2004,24(1):35-38.
6Poirel L,Naas T,Nicolas D,et al.Characterization of VIM-2,a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid-and integronborne gene from a Pseudomonas aeruginosa clinical isolate in France.Antimicrob Agents Chemother,2000,44(4):891-897.
7Walther-Rasmussen J,Johnsen AH,Hoiby N.Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa.Eur J Biochem,1999,263(2):478-485.
9Marchandin H,Jean-Pierre H,De Champs C,et al.Production of a TEM-24 plasmid-mediated extended-spectrum beta-lactamase by a clinical isolate of Pseudomonas aeruginosa.Antimicrob Agents Chemother,2000,44(1):213-216.
10Aubert D,Girlich D,Naas T,et al.Functional and structural characterization of the genetic environment of an extended-spectrum beta-lactamase blaVEB gene from a Pseudomonas aeruginosa isolate obtained in India.Antimicrob Agents Chemother,2004,48(9):3284-3290.
